Lauren A George1, Raymond K Cross2. 1. University of Maryland School of Medicine, 685 W. Baltimore St., Suite 8-00, Baltimore, MD, 21201, USA. 2. University of Maryland School of Medicine, 685 W. Baltimore St., Suite 8-00, Baltimore, MD, 21201, USA. rcross@som.umaryland.edu.
Abstract
PURPOSE OF REVIEW: Telehealth is the delivery of health care using the most recent technological advances. With the growing complexity of inflammatory bowel disease (IBD) care, telehealth allows for delivery of specialty services to an extended population. We reviewed the most recent literature on telehealth modalities, including patient-reported and disease outcomes associated with use of telehealth. RECENT FINDINGS: Current methods of telemedicine include telehealth, remote patient monitoring, and the use of mobile applications. Remote patient monitoring via web applications has been studied with improvement in patient-reported quality of life, medication adherence, and decreased heath care costs. Mobile applications can be used for symptom reporting and alert the medical team if a patient is reporting increased symptoms. These web and mobile applications allow for treatment decisions to occur without the delay of an office visit. There remain limitations to telehealth including technological concerns, physician acceptance, and licensing and reimbursement inequities. Telemedicine is a safe, effective, and accepted method of meeting the growing demand for complex IBD care throughout the world. The use of telehealth video conference and remote patient monitoring with web-based applications and text messaging has been shown to ease financial burdens of chronic disease, improve patient quality of life, and lead to improved clinical outcomes.
PURPOSE OF REVIEW: Telehealth is the delivery of health care using the most recent technological advances. With the growing complexity of inflammatory bowel disease (IBD) care, telehealth allows for delivery of specialty services to an extended population. We reviewed the most recent literature on telehealth modalities, including patient-reported and disease outcomes associated with use of telehealth. RECENT FINDINGS: Current methods of telemedicine include telehealth, remote patient monitoring, and the use of mobile applications. Remote patient monitoring via web applications has been studied with improvement in patient-reported quality of life, medication adherence, and decreased heath care costs. Mobile applications can be used for symptom reporting and alert the medical team if a patient is reporting increased symptoms. These web and mobile applications allow for treatment decisions to occur without the delay of an office visit. There remain limitations to telehealth including technological concerns, physician acceptance, and licensing and reimbursement inequities. Telemedicine is a safe, effective, and accepted method of meeting the growing demand for complex IBD care throughout the world. The use of telehealth video conference and remote patient monitoring with web-based applications and text messaging has been shown to ease financial burdens of chronic disease, improve patient quality of life, and lead to improved clinical outcomes.
Entities:
Keywords:
Inflammatory bowel disease; Mobile health applications; Remote monitoring; Telehealth
Authors: Raymond K Cross; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Joseph F Collins; Jonathan Katz; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Dawn Beaulieu; Sara N Horst; Katharine Russman; Mahrukh Riaz; Guruprasad Jambaulikar; Barathi Sivasailam; Charlene C Quinn Journal: Am J Gastroenterol Date: 2019-03 Impact factor: 10.864
Authors: N Pedersen; M Elkjaer; D Duricova; J Burisch; C Dobrzanski; N N Andersen; T Jess; F Bendtsen; E Langholz; S Leotta; T Knudsen; N Thorsgaard; P Munkholm Journal: Aliment Pharmacol Ther Date: 2012-11 Impact factor: 8.171
Authors: Katrine Carlsen; Christian Jakobsen; Gunnar Houen; Thomas Kallemose; Anders Paerregaard; Lene B Riis; Pia Munkholm; Vibeke Wewer Journal: Inflamm Bowel Dis Date: 2017-03 Impact factor: 5.325
Authors: Welmoed K Van Deen; Andrea E van der Meulen-de Jong; Nimisha K Parekh; Ellen Kane; Aria Zand; Courtney A DiNicola; Laurin Hall; Elizabeth K Inserra; Jennifer M Choi; Christina Y Ha; Eric Esrailian; Martijn G H van Oijen; Daniel W Hommes Journal: Clin Gastroenterol Hepatol Date: 2015-11-18 Impact factor: 11.382
Authors: Rosa Romero-Jimenez; Vicente Escudero-Vilaplana; Esther Chamorro-De-Vega; Arantza Ais-Larisgoitia; Maria Elena Lobato Matilla; Ana Herranz-Alonso; Maria Sanjurjo Journal: J Med Internet Res Date: 2022-03-04 Impact factor: 7.076
Authors: Johannes Knitza; Till Orlemann; Maximilian Gerner; Nicolas Vuillerme; Timothée Aubourg; Eva-Maria Messner; Yannik Terhorst; Verena Hörmann; Ingo Ganzleben; Hannah Schenker; Georg Schett; Raja Atreya; Markus F Neurath Journal: JMIR Mhealth Uhealth Date: 2022-05-03 Impact factor: 4.947
Authors: Emma Paulides; Annelieke Pasma; Nicole S Erler; Rachel L A van Eijk; Annemarie C de Vries; C Janneke van der Woude Journal: Dig Dis Sci Date: 2021-06-28 Impact factor: 3.487